

R. Castillejo García, F.A. Lao Dominguez, C. Moreno Ramos.

Clinical Pharmacist, Subdireccion General Farmacia. Servicio Extremeño de Salud, Merida, Spain.

## BACKGROUND AND IMPORTANCE

Migraine is a major contributor to hospital drug spending, and due to rising costs, increasing diagnoses, and the availability of new alternative treatments, pharmacists must develop protocols to ensure budget sustainability.

## AIM AND OBJECTIVES

Evaluate adherence to the hospital's migraine protocol after introducing oral Rimegepant and assess its economic impact.

## MATERIALS AND METHODS


All migraine medication prescriptions between March 2023 and March 2025 were retrospectively analysed.

Comparative study was conducted between the periods with and without the protocol (April 2023 to March 2024 vs April 2024 to March 2025).



The protocol established the first-line use of rimegepant, followed by eptinezumab, fremanezumab, erenumab and galcanezumab.

## RESULTS



The overall degree of compliance with the protocol was 66.67%, and the savings, the cost of choosing the best option, have been 20.480€ since the implementation of the protocol in the study period.



## CONCLUSION AND RELEVANCE

Our results show a high degree of compliance with the protocol as well as significant economic savings based on its implementation. In addition, the conditions of many patients already undergoing treatment improved when switching from subcutaneous to oral treatment.

